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Abstract
Background: We evaluated the orexin receptor antagonist filorexant (MK-6096) for treatment augmentation in patients with 
major depressive disorder.
Methods: We conducted a 6-week, double-blind, placebo-controlled, parallel-group, Phase II, proof-of-concept study. Patients 
with major depressive disorder (partial responders to ongoing antidepressant therapy) were randomized 1:1 to once-daily 
oral filorexant 10 mg or matching placebo.
Results: Due to enrollment challenges, the study was terminated early, resulting in insufficient statistical power to detect a 
prespecified treatment difference; of 326 patients planned, 129 (40%) were randomized and 128 took treatment. There was 
no statistically significant difference in the primary endpoint of change from baseline to week 6 in Montgomery Asberg 
Depression Rating Scale total score; the estimated treatment difference for filorexant-placebo was -0.7 (with negative values 
favoring filorexant) (P = .679). The most common adverse events were somnolence and suicidal ideation.
Conclusions: The interpretation of the results is limited by the enrollment, which was less than originally planned, but the 
available data do not suggest efficacy of orexin receptor antagonism with filorexant for the treatment of depression.
(Clinical Trial Registry: clinicaltrials.gov: NCT01554176)
Keywords: depression, filorexant, MK-6096, orexin receptor antagonist
Introduction
Insomnia shows high comorbidity with depression and is asso-
ciated with a 3- to 4-fold increased risk of developing the con-
dition (Breslau et al., 1996; Staner, 2010; Baglioni and Riemann, 
2012). Despite the availability of a wide range of antidepressant 
drugs, more than 50% of patients with major depressive disor-
der (MDD) fail to demonstrate an adequate response to first-line 
treatment. Switching to another antidepressant or treatment 
augmentation (i.e., adding a second agent) are commonly used 
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pharmacologic options for patients demonstrating inadequate 
treatment response; however, although successful for some, 
not all individuals experience improvement in their depressive 
symptoms (Fleurence et al., 2009).
The orexin signaling system, which originates in the lateral 
hypothalamus, plays an important role in sleep-wake control 
and may have additional functions, for example, regulation of 
stress, reward, and mood (Berridge et al., 2010; Gotter et al., 2012; 
Kukkonen and Leonard, 2014; Winrow and Renger, 2014; Yeoh 
et  al., 2014). Prior studies carried out in humans and animals 
provide a mixed picture as to what effects orexin antagonists 
would be expected to have when administered to patients with 
MDD. However, several of these studies are consistent with the 
possibility that orexin antagonism might improve depression. 
These studies include animal models of depression where ele-
vated orexin neuron activity was found (Mikrouli et  al., 2011), 
that treatment with the orexin receptor antagonist almorexant 
had antidepressant-like effects in the tail suspension test, ele-
vated plus maze, and resident-intruder task (Nollet et al., 2011), 
and that in a human study, orexin A CSF levels were found to be 
elevated in patients with depression and were lowered by treat-
ment with the antidepressant sertraline (Salomon et al.. 2003), 
although another study failed to find an elevation in CSF orexin 
A in depressed patients (Schmidt et al., 2011).
Filorexant (MK-6096) is an orally bioavailable potent and 
selective antagonist of orexin 1 and orexin 2 receptors (i.e., it is 
a dual orexin receptor antagonist) (Coleman et al., 2012; Winrow 
et al., 2012). In humans, filorexant has a short half-life of 3 to 6 
hours and has been shown to promote sleep onset and main-
tenance in patients with insomnia (Connor et al., 2016). Given 
the sleep-promoting properties of filorexant and the potential 
involvement of the orexin pathway in depression, it was hypoth-
esized that filorexant may have a role in the treatment of MDD.
This proof-of-concept study evaluated the safety, tolerabil-
ity, and efficacy of a sleep-promoting 10-mg dose of filorexant 
administered each night at bedtime compared with placebo for 
treatment augmentation in patients with MDD. The rationale for 
the dose selection in the current study was based on data from 
a study where patients with primary insomnia showed signifi-
cant improvements in sleep with filorexant 10 mg nightly with-
out the marked next-day somnolence in most patients (Connor 
et al., 2016). To our knowledge, this is the first study to evaluate 
the orexin receptor antagonist mechanism in MDD.
Methods
Study Design and Treatment
This was a 6-week, double-blind, placebo-controlled, rand-
omized (1:1), parallel-group study conducted between June 2012 
and September 2013 at 61 sites within Canada, Finland, France, 
Germany, Norway, Sweden, and the United States (clinicaltrials.
gov: NCT01554176).
The study comprised a screening period (≤2 weeks), a 6-week 
double-blind treatment period, and a 2-week double-blind, run-
out period for patients who completed the treatment period. 
During the treatment period, patients were randomized (1:1) 
to receive oral filorexant 10  mg once nightly (at bedtime) or 
matching placebo. Randomization was stratified by severity of 
depressive symptoms on the Hamilton Depression Rating Scale 
17-item (HAMD-17) (Hamilton 1960) total score (≤20 vs. >20) and 
extent of insomnia (Insomnia Severity Index [ISI] total score ≤14 
vs. >14) (Bastien et al. 2001). During the run-out period, patients 
initially randomized to filorexant received either filorexant or 
placebo, and patients initially randomized to placebo continued 
to receive placebo. Patients continued to take their prescribed 
pretrial antidepressant medication (selective serotonin reup-
take inhibitor, serotonin norepinephrine reuptake inhibitor, or 
bupropion) throughout the trial.
Patients
Patients were required to have a current primary diagnosis of 
recurrent MDD, without psychotic features, with a current mod-
erate or severe depressive episode, as defined by the DSM-IV-TR 
(American Psychiatric Association 2000) and as confirmed by the 
Mini International Neuropsychiatric Interview (Sheehan et al. 
1998) and clinical assessment. Male and female MDD patients 
(aged 21 to <65 years) were eligible for inclusion if they were partial 
responders to antidepressant therapy, defined as persistence of 
moderate to severe, nonpsychotic depressive symptoms, despite 
an adequate trial (dose and duration of treatment) of selective 
serotonin reuptake inhibitor, serotonin norepinephrine reuptake 
inhibitor, or bupropion monotherapy. Patients were excluded if 
they had an inadequate response (investigator's opinion) to more 
than three adequate antidepressant trials for treatment of the 
current depressive episode. Severity of depressive symptoms was 
based on the investigator’s clinical assessment, including the 
Montgomery Asberg Depression Rating Scale (MADRS) total score 
(Montgomery and Asberg 1979), and on patients’ assessment of 
their depressive symptoms using HAMD criteria. The HAMD-17 
was completed by patients at screening and baseline in the clinic 
using an interactive voice response system (Moore et al., 2006). 
The threshold for study entry was initially based on a HAMD Bech 
subscale (consisting of HAMD-17 items 1, 2, 7, 8, 10, and 13) score 
of ≥10 (Bent-Hansen and Bech, 2011); this was later changed to 
≥9 due to enrollment difficulties and feedback from study sites 
and external consultants. Both patients and sites were blinded 
to the HAMD threshold required for study entry in an attempt to 
minimize assessment bias and reduce placebo response. Patients 
were excluded if they were at imminent risk of self-harm, based 
on clinical interview and responses to item number 10 of the 
MADRS or on the Columbia Suicidality Severity Rating Scale 
(C-SSRS) (Posner et al. 2011), or if they reported suicidal ideation 
with intent, with or without a plan (i.e., MADRS item 10 ≥ 5 and/or 
Type 4 or 5 on the C-SSRS), in the past 1 month or suicidal behav-
ior in the past 6 months. Patients were also excluded if they were 
using anxiolytic or sedative-hypnotic agents chronically. Patients 
with narcolepsy were excluded.
All patients gave written informed consent to participate 
in the study. The study protocol (Protocol 022)  was approved 
by the relevant Institutional Review Board/Independent Ethics 
Committee at each participating center. The study was con-
ducted in accordance with good clinical practice and in compli-
ance with all local and/or national regulations and directives.
Efficacy Endpoints
Patients were evaluated in the clinic at the end of week 3 and 
week 6 of the treatment period and again at the end of the run-
out period (week 8). Patients also received follow-up phone call 1 
and 2 weeks after the last dose of study medication.
The primary endpoint was change from baseline to week 6 in 
the MADRS total score. Planned secondary endpoints included: 
change from baseline to week 6 in the MADRS total score, excluding 
the sleep item; change from baseline to week 6 in the HAMD Bech 
subscale score; change from baseline to week 6 in the HAMD-17 
total score; and HAMD-17 remission rate (i.e., HAMD-17 total score 
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≤7) at week 6. Exploratory endpoints were also planned, including 
change from baseline in HAMD-17 total score and ISI total score.
Safety and Tolerability
Safety was assessed based on the incidence and severity of 
adverse events (AEs). Prespecified events of clinical interest 
(ECIs) included suicidal ideation and/or behaviors, selected AEs 
associated with potential for abuse, overdose, complex sleep-
related behaviors, hypnagogic or hypnopompic hallucinations, 
excessive daytime sleepiness, sleep paralysis, sleep-onset paral-
ysis, cataplexy, and falls. Vital signs, body weight, electrocardio-
gram, physical and neurological examination, and laboratory 
evaluations were also assessed and the C-SSRS was completed 
(baseline, week 3, week 6, and run-out period).
Statistical Methods
The study was originally designed to include 326 patients (163 
per treatment group) to provide 80% power to detect a 3.5-point 
difference between treatments (based upon a 2-sided 5% level 
test) for the primary endpoint. This assumed a SD of 9.6 points 
and a 21% dropout rate and accounted for a planned interim 
futility analysis (not conducted due to early termination). This 
difference corresponds to a standardized effect size of 0.4.
Efficacy analyses were conducted using the full-analysis-set 
population (all randomized patients who received at least one 
dose of double-blind study treatment and had at least one evalu-
able endpoint measurement, including those patients who only 
had a baseline measurement). Efficacy endpoints (i.e., change 
from baseline in MADRS total score, MADRS score excluding 
sleep item, HAMD-17 total score, and HAMD Bech subscale 
score) were assessed using a constrained longitudinal data anal-
ysis model, including terms for treatment, time, time-by-treat-
ment interaction, severity of disease at baseline (HAMD-17 ≤20 
vs. >20), and insomnia at baseline (ISI ≤14 vs. >14) as categorical 
terms. This model assumes a common mean across treatment 
groups at baseline and a different mean for each postbaseline 
time point. Time is treated as a categorical variable so that no 
restriction is imposed on the trajectory of the means over time. 
An unstructured covariance matrix was used to model the cor-
relation among repeated measurements.
The all-patients-as-treated population was used for safety 
analyses (all randomized patients who received at least one 
dose of double-blind study treatment).
Results
A total of 129 patients, 40% of the originally planned popula-
tion (129/326), were randomized to treatment. Study treatment 
was administered to 128 of these patients and 116 patients com-
pleted the treatment period (Supplementary Figure 1). The study 
was terminated early because of low recruitment resulting from 
enrollment challenges. If the study had been designed with a 
sample size of 65 patients per treatment group (i.e., the approxi-
mate observed sample size), based on the assumptions already 
described, the study would have been underpowered (<50%) to 
detect a treatment difference in MADRS.
Patient characteristics were similar across treatment groups 
(Supplementary Table  1), with patients predominantly female 
(63.3%) and white (86.7%). Mean age was 48.8 years. The major-
ity (~80%) of patients had baseline insomnia (ISI total score >14). 
Mean baseline HAMD-17 total scores were ~24, consistent with 
moderate to severe depression.
Efficacy
Results for change from baseline in depression endpoints are 
summarized in Table 1. There was no statistically significant dif-
ference on the primary endpoint of mean change from baseline to 
week 6 in MADRS total score with filorexant vs. placebo (Table 1). 
The estimated treatment difference (filorexant–placebo) was -0.7 
(95% CI: -3.8, 2.5; P = .679), with a negative difference correspond-
ing to numerical improvement compared with placebo. This 
difference corresponds to a standardized effect size of -0.1. In 
addition, no significant difference between filorexant and placebo 
was observed in change from baseline to week 3 in MADRS total 
score. There were no significant differences between treatments 
on other change from baseline depression endpoints (Table  1). 
The percentages of patients with remission (HAMD-17 total score 
≤7) at week 6 were 12/56 (21.4%) for filorexant vs. 6/61 (9.8%) for 
placebo (estimated odds ratio = 2.5 [95% CI: 0.8, 7.3], P = .097).
Exploratory analyses were performed to assess whether filo-
rexant improved insomnia severity in this study, consistent with 
its known sleep-promoting properties. Surprisingly, no statisti-
cally significant improvements in the change from baseline in 
ISI total score were observed with filorexant vs. placebo at week 
3 or week 6 (mean [SD] change from baseline to week 6: -5.6 [6.2] 
with filorexant and -4.8 [5.5] with placebo; estimated treatment 
difference: -0.7 [95% CI: -2.8, 1.4], P = .481).
Safety and Tolerability
Twenty-seven patients (42%) in the filorexant group and 17 
patients (27%) in the placebo group reported AEs during the 
treatment period (Table 2). One patient in each treatment group 
discontinued due to an AE (filorexant: sedation; placebo: fibro-
myalgia). One serious AE (diverticulitis, not drug related) was 
reported in the filorexant group and did not result in treatment 
discontinuation. No deaths were reported. The most commonly 
reported AEs with numerically greater incidence for filorexant 
than placebo during the treatment period were somnolence and 
suicidal ideation (Table 2).
Two patients in the filorexant group reported ECIs of exces-
sive daytime sleepiness during the double-blind treatment 
period. Three ECIs were reported during the run-out period, 
one event of a fall in the placebo group, and 2 events of acci-
dental overdose (i.e., accidentally taking study medication) that 
occurred in one patient in the filorexant group. No AEs were 
reported in conjunction with the accidental overdose, which 
involved 2 occasions of accidentally taking more study medica-
tion than the prescribed dose.
In total, 13 unique patients reported suicidal ideation during 
the trial (based on AE/ECI reports and/or positive responses to 
the C-SSRS), including 10 patients during the treatment period 
(filorexant, n/N = 7/64; placebo, n/N = 3/64) and 9 patients dur-
ing the run-out period (filorexant [treatment]/filorexant [run-
out], n/N = 5/29; filorexant/placebo, n/N = 1/28; placebo/placebo, 
n/N = 3/59). None of the AEs of suicidal ideation (nine patients 
in total) were considered by the investigator to be related to 
the study drug. No suicidal behaviors or ideation with a plan or 
intent were reported. All but one patient had a prior history of 
suicidal ideation. Two patients reported the same level of idea-
tion at each visit throughout the study (filorexant, n = 1; placebo, 
n = 1), and 2 patients reported suicidal ideation at the randomi-
zation visit only, before taking the first dose of study medication 
(filorexant, n = 1; placebo, n = 1).
No clinically relevant mean changes in laboratory param-
eters or vital signs were observed during the study.
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Discussion
The study hypothesis, that filorexant would be superior to pla-
cebo as augmentation therapy in patients with MDD, could 
not be adequately tested because of low enrollment (40% of 
planned). The size of the observed, nonsignificant difference 
on the MADRS primary endpoint (0.7-point reduction/-0.1 
standardized effect size) was considerably smaller than the 
difference the study was powered to detect (3.5-point reduc-
tion/-0.4 standardized effect size), suggesting that even if the 
study had run to completion a significant effect would not have 
been found.
Our results argue against a direct antidepressant effect of 
orexin receptor antagonism in this population. As noted in the 
Introduction, the prior evidence supporting a direct antidepres-
sant effect of orexin receptor antagonism is limited. It is inter-
esting to consider whether an orexin receptor antagonist could 
indirectly help relieve depression through improving sleep. 
Although the majority (80%) of patients in our study had some 
degree of insomnia at baseline, improvements in insomnia 
symptoms were not observed with a dose of filorexant known 
to improve sleep in insomnia patients (Connor et al., 2016). It is 
unclear whether this lack of effect was due to underpowering or 
would have been impacted by features of the study population. 
As baseline insomnia was not required for inclusion, it is possi-
ble that effects of filorexant might differ in a cohort of depressed 
patients specifically selected based on insomnia symptoms. 
Had a significant effect on depression been demonstrated, it 
would have been important to distinguish whether the treat-
ment effect was primarily due to an improvement in depression 
or attributable to an improvement in insomnia with secondary 
improvement in depression. However, this was not explored 
Table  2. Summary of Adverse Events during the Treatment Period 
(All Patients as Treated)
Filorexant 10 mg  
(n = 64)
Placebo  
(n = 64)
Number (%) of patients
 With ≥1 AE 27 (42.2) 17 (26.6)
 With drug-related AEs 16 (25.0) 6 (9.4)
 With SAEs 1 (1.6) 0 (0)
 With drug-related SAEs 0 (0) 0 (0)
 Discontinued due to AEs 1 (1.6) 1 (1.6)
  Discontinued due to drug- 
related AE
1 (1.6) 0 (0)
 Discontinued due to a SAE 0 (0) 0 (0)
Common AEs (incidence ≥4 patients in either treatment group)
 Somnolence 5 (7.8) 0 (0)
 Suicidal ideationa 5 (7.8) 1 (1.6)
 Dizziness 0 (0) 4 (6.3)
 Headache 4 (6.3) 5 (7.8)
Abbreviations: AE, adverse event; SAE, serious adverse event.
aA total of 10 patients reported suicidal ideation during the treatment period 
based on AE/ECI reports and/or positive responses to the C-SSRS: filorexant 
=7/64 (10.9%), placebo, 3/64 (4.7%). See main text for further details.
Table 1. Summary of Change from Baseline Depression Scores at Week 3 and Week 6 (Full Analysis Set)
Baseline Timepoint Change from Baseline
Difference (Filorexant vs. 
Placebo)
Assessment N Mean (SD) Mean (SD) Mean (SD) LS mean (95% CI) LS mean (95% CI) P value
MADRS total score (primary endpoint)
Week 3
 Filorexant 10 mg 61 30.2 (4.6) 23.2 (8.0) -7.0 (6.2) -7.0 (-8.7, -5.3) -0.3  
(-2.7, 2.0)
0.770
 Placebo 62 30.9 (4.4) 24.3 (8.1) -6.6 (6.9) -6.6 (-8.3, -5.0)
Week 6
 Filorexant 10 mg 58 30.3 (4.6) 19.3 (9.7) -11.0 (9.5) -10.9 (-13.2, -8.7) -0.7  
(-3.8, 2.5)
0.679
 Placebo 61 31.0 (4.3) 20.7 (8.7) -10.3 (8.2) -10.3 (-12.5, -8.0)
MADRS score excluding sleep item
Week 3
 Filorexant 10 mg  61 26.4 (4.2)  20.4 (7.6)  -6.0 (5.8)  -6.0 (-7.5, -4.4) -0.2  
(-2.4, 1.9)
0.831
 Placebo  62 27.1 (4.2)  21.4 (7.5)  -5.7 (6.3)  -5.7 (-7.2, -4.2)
Week 6
 Filorexant 10 mg  58 26.5 (4.1)  17.0 (8.7)  -9.5 (8.5)  -9.4 (-11.5, -7.4) -0.3  
(-3.2, 2.5)
0.820
 Placebo  61 27.2 (4.1)  18.0 (8.0)  -9.1 (7.4)  -9.1 (-11.1, -7.1)
HAMD-17 total score
Week 3
 Filorexant 10 mg  59 24.0 (5.3)  17.5 (6.0)  -6.5 (6.3)  -6.6 (-8.1, -5.0) -0.9  
(-3.0, 1.3)
0.412
 Placebo  63 24.4 (4.9)  18.7 (6.7)  -5.7 (6.1)  -5.7 (-7.2, -4.2)
Week 6
 Filorexant 10 mg  56 23.9 (5.4)  15.7 (7.5)  -8.2 (8.7)  -8.1 (-10.1, -6.2) -0.5  
(-3.2, 2.1)
0.697
 Placebo  61 24.4 (4.9)  16.6 (7.0)  -7.8 (6.5)  -7.6 (-9.5, -5.7)
HAMD Bech subscale score
Week 3
 Filorexant 10 mg  59 13.1 (2.3)  9.3 (4.0)  -3.8 (3.5)  -3.8 (-4.8, -2.9) -0.7  
(-2.0, 0.5)
0.250
 Placebo  63 13.0 (2.1)  9.9 (3.7)  -3.0 (3.6)  -3.1 (-4.0, -2.2)
Week 6
 Filorexant 10 mg  56 13.1 (2.4)  8.4 (4.9)  -4.7 (4.8)  -4.6 (-5.7, -3.4) -0.3  
(-1.9, 1.3)
0.701
 Placebo  61 13.0 (2.1)  8.7 (4.0)  -4.2 (4.0)  -4.3 (-5.4, -3.2)
Based on a constrained longitudinal data analysis model with terms for treatment, time, the interaction of time by treatment, severity of disease measured by the 
Hamilton Depression Rating Scale 17-item (HAMD-17) total score (≤20, >20) and insomnia severity index total score (ISI ≤14, >14).
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due to the limited sample size and the observed results. Future 
studies might consider evaluating the effects of orexin receptor 
antagonists in patients with comorbid insomnia.
The low enrollment in our study suggests that the inclusion/
exclusion criteria were too “restrictive.” However, our intent was 
to exclude treatment-refractory patients. To be less restrictive 
would have resulted in a more heterogeneous population, which 
would have led to difficulties in interpreting the results.
Another factor that complicates interpretation of the results 
was the need to administer filorexant at bedtime to avoid day-
time sedation resulting from its known hypnotic effect (Connor 
et al., 2016). It is unknown whether pharmacological activity 
during wakefulness would be required for the orexin receptor 
antagonist to provide a benefit on symptoms of depression. It 
is also possible that a higher dose of an orexin receptor antago-
nist is necessary to treat depression than insomnia, although 
administering a higher dose would likely not be clinically ten-
able due to the potential for increased next-day somnolence.
The observed safety profile of filorexant in depressed patients 
was generally similar to that reported with compounds in the 
same class, such as suvorexant and almorexant, in healthy sub-
jects and insomnia patients (Bettica et al., 2012; Herring et al., 
2012, 2016; Hoever et al., 2012; Cruz et al., 2014; Michelson et al., 
2014), with somnolence being the most common adverse event. 
Not surprisingly, given the depressed population, suicidal idea-
tion was reported more commonly in this study than in stud-
ies of primary insomnia patients (Michelson et al., 2014; Herring 
et al., 2016).
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